

- ¹⁸F-FDG PET SUV repeatability:** Lodge reviews available data on repeatability metrics, relative units, log transformation, and asymmetric limits of repeatability in ¹⁸F-FDG SUV assessment. **Page 523**
- Metabolic imaging of glutamine:** Zhu and colleagues provide an overview of the potential utility of ¹¹C- and ¹⁸F-labeled glutamine tracers for targeting in vivo metabolism of glutamine in cancer cells. **Page 533**
- Imaging human immune checkpoints:** Mayer and colleagues optimize noninvasive immuno-PET imaging of human programmed death-ligand 1 expression in a preclinical model, using a small high-affinity engineered protein scaffold. **Page 538**
- Bimodal molecular imaging:** Lee and colleagues test the ability of a laparoscopic camera system to detect fluorescent signal emanating from sentinel lymph nodes 2 d after injection of fluorescent-tagged tilmanocept radiolabeled with both ⁶⁸Ga and ^{99m}Tc. **Page 547**
- ¹⁸F-FHNP for ERβ expression:** Antunes and colleagues report on synthesis and in vitro and in vivo evaluations of a potential estrogen receptor isoform β-selective PET tracer. **Page 554**
- ¹⁸F-FES PET in breast cancer:** Fowler and Linden offer background and perspective on an article in this issue of *JNM* on ¹⁸F-FES PET/CT prediction of pathologic response to neoadjuvant therapy in patients with estrogen receptor-positive primary breast tumors. **Page 560**
- ¹⁸F-FES PET in ER-rich breast cancer:** Chae and colleagues investigate the ability of ¹⁸F-fluoroestradiol PET/CT imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor-rich breast cancer. **Page 563**
- Radiomics and somatic mutations:** Yip and colleagues assess associations (including predictive utility) between ¹⁸F-FDG PET-based radiomic features and somatic mutations in patients with non-small cell lung cancer. **Page 569**
- PET/CT, timing, and pediatric HL:** Bakhshi and colleagues report on the significance of interim and end-of-treatment ¹⁸F-FDG PET/CT in children with Hodgkin lymphoma, including comparisons with conventional contrast-enhanced CT and Deauville 5-point response assessment. **Page 577**
- ¹⁸F-FET PET in brain mets:** Unterrainer and colleagues detail ¹⁸F-FET uptake characteristics on PET imaging in patients with newly diagnosed and untreated brain metastases and describe potential utility in treatment response assessment. **Page 584**
- Evans blue-based theranostics:** Chen and colleagues detail development of an “add-on” molecule containing a truncated Evans blue dye molecule for prolonged half-life, a metal chelate for radiolabeling in imaging and radiotherapy, and maleimide for conjugation to drug molecules. **Page 590**
- α-RIT cure of xenografts:** Bäck and colleagues explore the influence of targeted ²¹¹At-radioimmunotherapy on macrotumor treatment, long-term toxicity, and survival in an ovarian cancer mouse model. **Page 598**
- PET/CT MPI and radiation damage:** Song and colleagues determine the potential value of ¹³N-ammonia PET/CT myocardial perfusion imaging for early detection of perfusion changes induced by radiation damage. **Page 605**
- Quantitative small-animal PET:** Huang and colleagues demonstrate in a physiologically stable rat model the feasibility of quantitative small-animal ¹⁸F-FDG PET by repeated imaging to monitor the time course of variations in the cerebral metabolic rate of glucose utilization. **Page 611**
- Small-animal PET and HD:** Häggkvist and colleagues use a recently reported mouse model in small-animal PET imaging with a range of radioligands to characterize the progression of molecular targets associated with Huntington disease. **Page 617**
- Tau quantification with ¹⁸F-AV1451:** Hahn and colleagues outline different strategies for quantification of ¹⁸F-AV1451 tau binding, including models with blood sampling and noninvasive alternatives, with potential for applications in neurodegenerative disease. **Page 623**
- ¹⁸F-FDG PET in PCA and DLB:** Whitwell and colleagues determine whether patterns of hypometabolism or the cingulate island sign differ in patients with clinically diagnosed posterior cortical atrophy or probable dementia with Lewy bodies. **Page 632**
- Prediction of Aβ accumulation:** Guo and colleagues investigate whether regional patterns of longitudinal β-amyloid accumulation can be predicted by baseline amyloid ¹⁸F-florbetapir PET imaging in patients with incipient and manifest dementia associated with Alzheimer disease. **Page 639**
- Hybrid detection modalities:** KleinJan and colleagues describe clinical applications of 2 configurations, each of which combines γ-detection and an open surgery fluorescence camera, in guiding sentinel node biopsy with an indocyanine green-^{99m}Tc-nanocolloid. **Page 646**
- Clustering of dynamic PET tumor images:** Katiyar and colleagues devise and validate an unsupervised segmentation algorithm for assessment of tumor heterogeneity using dynamic ¹⁸F-FDG PET. **Page 651**
- ⁹⁰Y PET/CT image reconstruction with BPL:** Rowley and colleagues evaluate new reconstruction software using a Bayesian penalized likelihood reconstruction algorithm in phantom and patient PET scans after selective internal radiotherapy. **Page 658**
- ^{99m}Tc-duramycin SPECT and therapy response:** Elvas and colleagues compare the predictive power of cell death imaging using ^{99m}Tc-duramycin SPECT with the current gold standard ¹⁸F-FDG PET for treatment response evaluation after targeted therapy. **Page 665**
- PET imaging of αvβ6 integrin:** Notni and colleagues describe preclinical PET imaging of the cellular transmembrane receptor αvβ6 integrin using ⁶⁸Ga-labeled nonapeptides, with a wide range of potential clinical utilities. **Page 671**
- ABC11 function at blood-retina barrier:** Bauer and colleagues assess P-glycoprotein transport activity at the human blood-retina barrier using (R)-¹¹C-verapamil PET. **Page 678**